Drug Trial Radar · NCT04292314
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
Last checked: Nov 19, 2026Latest source record: Jan 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Nov 1, 2019
Primary completion
Dec 20, 2020
Study completion Jan 20, 2021
Sponsor
- Lead sponsor
- Beni-Suef UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Maternity and Children Hospital, Makkah; Beni-Suef Health insurance hospital; University of Arizona
- First posted
- Mar 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 7 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the present study is evaluating the strength of combination therapy of hydroxy urea, omega 3, nigella sativa and honey on antioxidant-oxidant status (OXIDATIVE STRESS) in response to reactive oxygen species production (LIPID PEROXIDATION) and their effect on iron intoxication (IRON CHELATION) in pediatric major thalassemia.
Conditions
- Iron Overload
- Oxidative Stress
- Thalassemia Major
Interventions
Omega 3Drug
Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
Nigella Sativa OilDrug
Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
HydroxyureaDrug
hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
HoneyDrug
Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
DeferoxamineDrug
deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
blood transfusion sessionProcedure
Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- F 2 -isoprostanes pg/mLTime frame: 3 months
- Total cholesterol Mg/dlTime frame: 10 months
- HDL cholesterol Mg/dlTime frame: 10 months
- LDL cholesterol Mg/dlTime frame: 10 months
- Triglycerides Mg/dlTime frame: 10 months
- Serum total iron mcg/dLTime frame: 10 months
- % transferrin saturationTime frame: 10 months
- C-reactive protein mg/LTime frame: 10 months
- Serum Ferritin ng/mlTime frame: 10 months
- Total Iron Binding Capacity (TIBC) mcg/dLTime frame: 10 months
- hemoglobin (Hbg) g/dLTime frame: 10 months
- mean corpuscular hemoglobin (MCH) pg/mlTime frame: 10 months
- leukocytes count μlTime frame: 10 months
- % Chelation activity Fe+++ - thymoquinone complexTime frame: 3 months
- % Chelation activity Fe++ - thymoquinone complexTime frame: 3 months
- Lactic acid dehydrogenase U/LTime frame: 10 months
- Reticulocyte count %Time frame: 10 months
- Hb-F level g/dLTime frame: 10 months
- Reticulocyte absolute countTime frame: 10 months
- White blood cells countTime frame: 10 months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital
Banī Suwayf, Egypt
Faculty of Pharmacy, Beni-Suef university
Banī Suwayf, Egypt
Health insurance hospital
Banī Suwayf, Egypt
Maternity and Children hospital
Mecca, Saudi Arabia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.